$XENE Xenon Pharmaceuticals Inc. Insider Trading Week 11/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Xenon Pharmaceuticals Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Xenon Pharmaceuticals Inc. in week 11/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.56 | 3,086 | 10,986 | 0 | |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.07 | 4,629 | 14,211 | 0 | |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.77 | 4,115 | 15,514 | 0 | |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.67 | 5,144 | 18,878 | 0 | |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.76 | 25,720 | 96,707 | 0 | |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.70 | 18,004 | 66,615 | 0 | |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.56 | 3,086 | 10,986 | 30,348 | 27.3 K to 30.3 K (+11.32 %) |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.07 | 4,629 | 14,211 | 27,262 | 22.6 K to 27.3 K (+20.45 %) |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.77 | 4,115 | 15,514 | 22,633 | 18.5 K to 22.6 K (+22.22 %) |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.67 | 5,144 | 18,878 | 146,187 | 141 K to 146.2 K (+3.65 %) |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.76 | 25,720 | 96,707 | 141,043 | 115.3 K to 141 K (+22.30 %) |
| Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.70 | 18,004 | 66,615 | 115,323 | 97.3 K to 115.3 K (+18.50 %) |
| Mar 14 2017 | XENE | Xenon Pharmaceutic ... | EMPFIELD JAMES R. | SVP, Drug Discovery | Option Exercise | A | 8.40 | 27,500 | 231,000 | 27,500 | |
| Mar 14 2017 | XENE | Xenon Pharmaceutic ... | COHEN CHARLES J. | VP, Biology | Option Exercise | A | 8.40 | 20,000 | 168,000 | 20,000 | |
| Mar 14 2017 | XENE | Xenon Pharmaceutic ... | WINQUIST RAYMOND | Head, Translational ... | Option Exercise | A | 8.40 | 20,000 | 168,000 | 20,000 | |
| Mar 14 2017 | XENE | Xenon Pharmaceutic ... | MORTIMER IAN | CFO & COO | Option Exercise | A | 8.40 | 75,000 | 630,000 | 75,000 | |
| Mar 14 2017 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | SVP, Clinical Devel ... | Option Exercise | A | 8.40 | 27,500 | 231,000 | 27,500 |